Valuation: BLS Pharmaceuticals Limited

Market Cap 235M 163M 144M 135M 123M 232M 15.66B 1.63B 633M 7.97B 611M 597M 25.61B P/E 2025
17.8x
P/E 2026 13.9x
Enterprise Value 230M 159M 141M 132M 121M 227M 15.33B 1.6B 619M 7.81B 598M 585M 25.08B EV / Sales 2025
2.82x
EV / Sales 2026 2.82x
Free-Float
41.59%
Yield 2025 *
-
Yield 2026 -
1 day-0.49%
1 week-1.46%
Current month-3.33%
1 month-8.14%
3 months+7.98%
6 months+58.59%
Current year+141.67%
1 week 0.94
Extreme 0.945
1.12
1 month 0.94
Extreme 0.945
1.3
Current year 0.36
Extreme 0.36
1.3
1 year 0.33
Extreme 0.33
1.3
3 years 0.04
Extreme 0.04
1.3
5 years 0.04
Extreme 0.04
1.3
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 2023-05-18
Director of Finance/CFO 72 2016-08-31
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 2012-12-04
Director/Board Member 72 2022-06-29
Director/Board Member - 2023-05-18
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Buy 5,000,000 0.2202%
5/14/26 Exercice 5,000,000 0.2202%
3/22/26 Buy

Chief Executive Officer

1,800,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-1.46%+147.56%+822.73% 168M
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
-1.78%+8.00%+36.77%+22.78% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.09%-0.98%+63.36%+221.12% 39.7B
Weighted average by Cap. +0.17%+0.11%+58.39%+146.07%

Financials

2025 2026
Net sales 29.28M 20.27M 18M 16.84M 15.34M 28.88M 1.95B 204M 78.84M 994M 76.1M 74.45M 3.19B 73.91M 51.16M 45.44M 42.5M 38.73M 72.91M 4.93B 514M 199M 2.51B 192M 188M 8.06B
Net income 4.9M 3.39M 3.01M 2.82M 2.57M 4.83M 327M 34.09M 13.2M 166M 12.74M 12.46M 534M 15.4M 10.66M 9.47M 8.85M 8.07M 15.19M 1.03B 107M 41.46M 523M 40.02M 39.15M 1.68B
Net Debt -6.13M -4.25M -3.77M -3.53M -3.21M -6.05M -409M -42.67M -16.52M -208M -15.94M -15.6M -669M -4.86M -3.36M -2.99M -2.79M -2.54M -4.79M -324M -33.78M -13.08M -165M -12.62M -12.35M -529M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
26-10-01 A$1.015 -0.49% 804
26-10-01 A$1.020 -2.86% 238,588
26-09-30 A$1.050 +5.53% 210,245
26-09-29 A$0.9950 -1.97% 584,377
26-09-28 A$1.015 -1.46% 817,109

Annual profits - Rate of surprise